The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
The test combines sensitivity with speed and is designed to be used in health care settings to aid with rapid diagnosis of Covid-19
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Second interchangeable biosimilar product approved by agency
ICICI Direct gives an update on the 12 companies that it has covered in the healthcare universe. A report
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Equity raise to finance growth and investments in the biological space
Subscribe To Our Newsletter & Stay Updated
